<MedlineCitation Status="Completed">
<MedlineID>10011471</MedlineID>
<PMID>570425</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3002</ISSN>
<JournalIssue>
<Volume>582</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Stereospecific (--)-[3H]norepinephrine binding to bovine hypothalamus. Possible identification of the catecholamine uptake site in synaptic vesicles.</ArticleTitle>
<Pagination>
<MedlinePgn>470-85</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>A (--)-[3H]norepinephrine binding site was identified in a crude synaptosomal fraction isolated from bovine hypothalamus which bound norepinephrine rapidly, reversibly, and stereospecificially. The results were most consistent with binding of (-)-[H]norepinephrine to the carrier molecule used to translocate biogenic amines into synaptic vesicles. The binding studies indicated that specific binding of (--)-[3H]norepinephrine to the crude synaptosomal fraction was greatly enhanced by 4 mM MgCl2 pand 1 mM ATP. The increased binding of (--)-[3H5norepinephrine also occurred in the presence of MgCl2 and GTP, but AMP, adenosine and adenyl-5'-yl imidodiphosphate would not substitute for ATP. Neither CaCl2 nor ZnSO4 could be substituted for the MgCl2. In the presence of MgCl2 and ATP, the dissociation constant for (--)-[3H]norepinephrine was 280 nM with a specific binding site density of 4.8 pmol/mg protein. Binding was stereospecific with ratios of 15, 4, and 6.5 for the affinities of (--)-isomers to (+)-isomers for norepinephrine, epinephrine and isoproterenol, respectively. Drug competition studies, conducted in the presence of Mg2+ and ATP, indicated that (--)-epinephrine, (--)-norepinephrine, dopamine and serotonin had inhibitory constants ranging from 0.25 to 0.8 micron with (--)-isoproterenol and tyramine having inhibitory constants around 2 micron. Reserpine was the most potent inhibitor having an inhibition constant of 8.6 +/- 0.3 nM. The binding data were not consistent with the specific site being the alpha- or beta-receptors for norepinephrine, the Uptake1 Site for norepinephrine into synaptosomes or the metabolizing enzymes for norepinephrine.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Deupree</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Author>
<Author>
<LastName>Kennedy</LastName>
<ForeName>R H</ForeName>
<Initials>RH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Biochim Biophys Acta</MedlineTA>
<NlmUniqueID>0217513</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Adenine Nucleotides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Biogenic Amines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cations, Divalent</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-55-5</RegistryNumber>
<NameOfSubstance>Reserpine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-41-2</RegistryNumber>
<NameOfSubstance>Norepinephrine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-65-5</RegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7439-95-4</RegistryNumber>
<NameOfSubstance>Magnesium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7683-59-2</RegistryNumber>
<NameOfSubstance>Isoproterenol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adenine Nucleotides</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adenosine Triphosphate</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding, Competitive</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Biogenic Amines</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cations, Divalent</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cattle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hypothalamus</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Isoproterenol</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Magnesium</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Norepinephrine</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Reserpine</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Synaptic Vesicles</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
